Rachael Cella

Rachael Cella

Auto-generated profile, based on publicly available information

Rachael Cella

University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2025 in Journal of Affective Disorders
Verified
Journal Article
Closed access
RCRachael Cella
Rachael Cella
LWLihong Wang
Lihong Wang
RWRong Wu
Rong Wu
JFJulian D. Ford
Julian D. Ford
GPGodfrey D. Pearlson
Godfrey D. Pearlson
DSDavid C. Steffens
David C. Steffens

1 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RCRachael Cella
Rachael Cella
HBHelen Bian
Helen Bian
ALAlexander Luo
Alexander Luo
BABushra Alfakhri
Bushra Alfakhri
SMShanzay Malik
Shanzay Malik
GRGualberto Ruaño
Gualberto Ruaño
Pharmacogenomics (PGx) uses the variation in a patient’s genetic profile to assist with medication choice, with the goal of shortening the trial-and-error process of prescribing in psychiatry. Over the past few decades, PGx technology has evolved greatly to identify various genetic polymorphisms in drug-metabolizing enzymes; however, clinical use and relevance of PGx in child and adolescent psychiatry (CAAP) remain limited. This narrative review explores the historical evolution of PGx, compares key technological advancements, and evaluates their clinical relevance to CAAP. We address current barriers to PGx implementation, including developmental differences in pharmacokinetics between adults and children, the lack of robust evidence of clinical efficacy in youth populations, and inconsistent guidelines causing clinician confusion. We also highlight the need for clinical decision support (CDS) tools and broader practical and ethical considerations before widespread uptake of PGx would be feasible.